Navigation Links
AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease

obal markets, integrating device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes. Cook won the prestigious Medical Device Manufacturer of the Year for 2006 from Medical Device and Diagnostic Industry magazine. For more information, visit www.cookmedical.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Contact

AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
hubbard@avibio.com
or
Lippert/Heilshorn & Associates Inc.
AVI Investor Contacts
Jody Cain, 310-691-7100
jcain@lhai.com
or
Brandi Floberg, 310-691-7100
bfloberg@lhai.com
or
Waggener Edstrom Worldwide Healthcare Practice
AVI Press Contact
Jenny Moede, 503-443-7000
jmoede@waggeneredstrom.com


'"/>




Page: 1 2

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. GenoLogics Announces Bioinformatics Partnership with Illumina
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/4/2009)INDIANAPOLIS, Dec. 4 The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes
(Date:12/4/2009)Workers Ensure Emergency Deliveries are Transported ,, PHILADELPHIA, Dec. 4 Teamster members employed by the Philadelphia chapter of the American Red Cross are hard at work educating the public abo
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 1Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 2Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 3Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 4Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 5Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 6Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 7Endologix Reports 42 25 Second Quarter 2009 Revenue Growth 52461 8Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 1Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 2Gene Mutation Could Be Key to Rare Blood Vessel Disease 52456 3Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 1Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 2Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech Inc Sales in Emerging Markets 13155 3
...d Muscle Society International Congress, SOUTH PL...TC), a biopharmaceutical company focused on the di...l-molecule drugs targeting,post-transcriptional co...from a Phase 2 clinical trial of PTC124 in patient...nonsense mutation. The results, which include data...
... Trial Results of First Pro-Healing Stent Also ...ONG KONG, Oct. 18 OrbusNeich,s Genous(TM),Bio-eng...ions about,innovation in interventional cardiology...catheter Cardiovascular Therapeutics symposium, TC...on Convention Center in,Washington, D.C. The line...
Other Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007 2
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
...duces personality types used frequently in consume...e are motivated by one of two fundamental needs: t... that will help them achieve hopes and aspirations... exercise self-control when they choose goal-pursu...
...ervice to Retail Markets, MUNDELEIN, Ill., Jan. 2...day the retail launch of its headline-making,salad...e will consist of Z Trim Ranch, Z,Trim Honey Dijon...ht to transfer some of our success from Z,Trim pro...
...special needs child, Chelle Brewer,s, story of tri...spouse alpha moms worl...ewer,s soldier,husband is nearing the end of a hal...a heart. She volunteers for the,USO, Soldier,s Lis...
...s that seem to influence outcome , , WEDNE...ns that predict patient response to the two common...a) and venlafaxine (Effexor) have been identified ...protein called P-gp, which removes drugs and other...
...ap or press a surface is essential for everyday li...y or an iPhone. But researchers at the University...ivial action is the result of a complex neuro-moto...omedical engineer Francisco Valero-Cuevas is worki...
...ef, researchers say , , WEDNESDAY, Jan. 23... back pain, non-steroidal anti-inflammatory drugs ...e effective than acetaminophen. , That,s the concl...SAIDs are "slightly effective" for short-term symp...
Other Medicine News:Health News:Your personality type influences how much self-control you have 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 2Health News:Z Trim Holdings, Inc. Launches Innovative Retail Line of Lower Fat Salad Dressings in Upscale Grocery Chain 3Health News:'Military Spouse of the Year 2008' Announced 2Health News:Genetics May Determine Antidepressants' Effectiveness 2Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:NSAIDs No Better for Low Back Pain 2
... allows the physician to intubate the canaliculi i...anesthetic drops., ,The SRS is made of medical...25mm, 30mm and 35mm (disposable sizers sold separa...d head to provide fixation. Each head consists of ...
...s a peptide highly dependent on growth hormone and...ansported in serum by several IGF-binding proteins...ts of IGF-I are a useful adjunct to assessment of ... IGF-I concentration is strong evidence against GH...
...ystem built around the many positive attributes ,...of Logic Driven Incubation (LDI). LDI technology ,...ance with the fastest possible incubation times. ,...iac biomarkers and HCG to be run in around 15 ,m...
ACS:180 C-Peptide Assay
Medicine Products: